
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
CRBP | NASDAQ | USD | Real-time | |
0SZI | London | USD | Real-time | |
3371 | TradeGate | EUR | Delayed | |
3371 | Frankfurt | EUR | Delayed |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Alan F. Holmer | 71 | 2014 | Independent Chairman |
Yuval Cohen | 46 | 2014 | CEO & Director |
Rachelle Suzanne Jacques | 53 | 2019 | Independent Director |
Stephen L. Nishimura | - | - | Member of Scientific Advisory Board |
John Kenneth Jenkins | 66 | 2018 | Independent Director |
Anne Altmeyer | 59 | 2022 | Independent Director |
Peter Salzmann | 56 | 2020 | Independent Director |
Yong Ben | 50 | 2023 | Independent Director |
Winston Kung | 48 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review